<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">708</article-id><article-id pub-id-type="doi">10.36691/RJA708</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Atopic dermatitis. When and how to use topical corticosteroiods?</article-title><trans-title-group xml:lang="ru"><trans-title>Атопический дерматит. Когда и как использовать топические глюкокортикостероиды?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fedenko</surname><given-names>E S</given-names></name><name xml:lang="ru"><surname>Феденко</surname><given-names>Елена Сергеевна</given-names></name></name-alternatives><email>efed57@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Immunology</institution></aff><aff><institution xml:lang="ru">ФГБУ «ГНЦ Институт иммунологии» ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2012</year></pub-date><volume>9</volume><issue>3</issue><issue-title xml:lang="en">NO3 (2012)</issue-title><issue-title xml:lang="ru">№3 (2012)</issue-title><fpage>32</fpage><lpage>36</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, Фармарус Принт Медиа</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2014-12-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/708">https://rusalljournal.ru/raj/article/view/708</self-uri><abstract xml:lang="en"><p>Atopic dermatitis is a disease characterized with increasing prevalence around the world. It has chronic relapsing course and has a negative impact on the quality of life. Topical steroids (TS) due to their mechanisms of action remain the mainstay of topical treatment for AD patients. At the same time, well known side effects associated with corticosteroid therapy, although seen more frequently with incorrect TS use, and rare with the use of modern TS, in some instances limit their use. That is a reason for proper selection of topical treatment algorythms of AD including emollients and other medications in addition to the TS.</p></abstract><trans-abstract xml:lang="ru"><p>Проблема атопического дерматита (АтД) в последние десятилетия становится все более актуальной, поскольку число больных увеличивается с каждым годом. Хроническое течение АтД часто приводит к социальной дезадаптации и ухудшению качества жизни. Одной из важнейших составляющих комплексного лечения больных АтД является рациональная наружная терапия, в которой топические глюкокортикостероиды (ТГКС) занимают лидирующее положение благодаря их механизму действия. Вместе с тем, известные побочные эффекты этих препаратов, несмотря на то, что встречаются они чаще при неправильном применении, а для многих современных ТГКС частота их в принципе невысока, во многих случаях ограничивают использование этих препаратов. Поэтому подбор оптимальных схем наружной терапии АтД, включая уход за кожей, является крайне важной задачей для врача любой специальности.</p></trans-abstract><kwd-group xml:lang="en"><kwd>atopic dermatitis</kwd><kwd>topical treatment</kwd><kwd>topical corticosteroids</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>наружная терапия</kwd><kwd>топические глюкокортикостероиды</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bieber T. Atopic Dermatitis. The N. Eng J. Med. 2008, v. 358, p. 1483-1494.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Brown S., Irvine A. Atopic eczema and the filaggrin story. Semin Cutan Med. Surg. 2008, v. 27, p. 128-137.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>O’ Regan G.M., Irvine A.D. The role of filaggrin loss of function mutations in atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2008, v. 8, p. 406-410.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Elias P., Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2009, v. 9, p. 437-446.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Гущин И.С. Эпидермальный барьер и аллергия. Росс. Аллергол. Журн. 2007, № 2, с. 3-16.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Akdis C.A. Review article Diagnosis and treatment of atopic dermatitis in children and adults: Europian Academy of Allergology and Clinical Immunology, American Academy of Allergy, Asthma and Immunology. PRACTAlL Consensus report. Allergy. 2006, v. 61, p. 969-987.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Prakash A., Benfield P. Topical Mometasone. A Review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998, v. 55 (1), p. 145-163.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Barnes P.J. New directions in allergic diseases: mechanism based antiinflammatory therapies. J. Allergy Clin. Immunology. 2000, v. 106, p. 5-16.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Popper T.L., Gentles M.J., Kung T.T. et al. Structure activity relationship of series of novel topical corticosteroids. J. Steroid Biochem. Mol. Biol. 1987, v. 27 (4-6), p. 837-843.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Sharon E. Jacob, MD, Tace Steele, BA. Corticosteroid classes: A quick reference guide including patch test substances and cross-reactivity. j. am. acad. dermatol. april 2006.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Barton B.E., Jakway J.P., Smith S.R. Cytokine inhibition by a Novel Steroid, Mometason Furoat, Immunpharmacol. and Immunotoxicol. 1991, v. 3, p. 251-261.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Емельянов А.В., Монахов К.Н. Молекулярные механизмы действия топических глюкокортикоидов: значение внегеномного эффекта. Укр. журн. дерматол., венерол. и косметол. 2003, № 3, c. 38-40.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Vernon H.J., Lane A.T., Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J. Am. Acad. Dermatol. 1991, Apr. 24, p. 603-607.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Rafanelli A., Rafanelli S., Stanganelli I., et al. Mometasone furoate in the treatment of atopic dermatitis in children. J. Eur. Acad. Dermatol. Venereol. 1993, v. 2 (3), p. 225-230.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Veien N.K., Holmp P., Larsen et al. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. British Journal of Dermatology. 1999, v. 140, p. 882-886.</mixed-citation></ref></ref-list></back></article>
